and has now fallen 5 days in a row. In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. The company is aiming to transform the treatment of mental health disorders. As of 2021 November 14, Sunday current price of ATAI stock is 14.890$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). We would like to show you a description here but the site won’t allow us. ATAI is expected to have a valuation of $1 - $2 billion based on its IPO price. Psychedelic Stock Watch sees that as a conservative figure given its capitalization and strong R&D portfolio. If the expected IPO pricing is correct, there should be some nice gains available off of that IPO price. This suggests a possible upside of 127.2% from the stock's current price. ATAI Life Sciences NV (ATAI:NMQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In trading on Wednesday, shares of ATAI Life Sciences NV (Symbol: ATAI) entered into … About ATAI. See the latest earnings results for ATAI, Explore ATAI Life Sciences N.V.'s earnings history, its beat/miss ratio and find out the outlook for next earnings reports. The relatively young startup has a handful of founders, one of whom is … About atai Life Sciences. 9 analysts offering 12-month price targets in the last 3 months for ATAI Life Sciences evaluate the company at an average price target of $27.89 with a high of $45.00 and a low of $19.00. Since Atai Life Sciences is only going public, we don’t have any forecast for the stock. September 15, 2021. Share . About the ATAI Life Sciences N.V. stock forecast. ATAI is planning to offer their shares to the public in an IPO that expects to raise $100 million. Revenue in USD (TTM)--Net income in USD--Incorporated--Employees 35.00; Location ATAI Life Sciences NV c/o Mindspace, Krausenstrasse 9-10 Berlin 10117 Germany DEU; Phone +49 8 921539035 ATAI Life Sciences NV's share price could stay at $31.00 by Nov 22, 2022. Date Range. The six companies that listed their shares are all in the biotech or healthcare space. BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. Founded in 2018, ATAI Life Sciences is a German biotech startup that has raised $304 million in disclosed funding to build a holding company that creates, invests in, or acquires businesses developing psychedelic therapies. The company has an average price target of $30.6 with a … ATAI's earnings per share (EPS) was $-0.37, missing the consensus analysts forecast of $-0.18 by -102.19%. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. View atai Life Sciences N.V. ATAI investment & stock information. BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. Forecast & Beta. Big IPOs in an emerging industry are exciting events – and not just for the company going public. The last closing price of the ATAI Life Sciences N.V. share was $13.50 and has changed by 4.09% since the penultimate trading day. atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care. Get the latest atai Life Sciences N.V. ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. There has been speculation that ATAI’s IPO might come sooner than expected. ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Revenues were $0.00. ATAI Life Sciences B.V. ( ATAI) intends to raise $200 million from the sale of its common stock in an IPO, according to an amended registration statement. BC Craft works with local artists cross-sector and remains fervently committed to keeping the art, technique, and purity of their pursuit. Beta is calculated using regression analysis. BERLIN and NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update. The stock's open price was 14.85.Atai Life has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Butterfly Network, Inc. (NYSE: BFLY ) dipped 12.6% … The company is aiming to transform the treatment of mental health disorders. life ; EU Commission raises 2021 euro zone growth forecast, sees strong 2022; Global shares are mixed as Inflation, and the possible central bank reaction to it, remains a dominant theme in markets. ATAI LIFE SCIENCES N.V. : Forcasts, revenue, earnings, analysts expectations, ratios for ATAI LIFE SCIENCES N.V. Stock | ATAI | NL0015000DX5 We would like to show you a description here but the site won’t allow us. atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. This stock just amazes me every day. Over the short-term, Psychedelic Stock Watch sees the best investment opportunities from this IPO in other psychedelic stocks. Atai Life Sciences is backed by billionaire Peter Theil, who co-founded PayPal and Palantir. Atai Life Sciences has also filed for an IPO. What’s the forecast for Atai Life Sciences stock and should you buy the IPO? Atai Life Sciences is a Berlin-based biotech startup. The company is working to treat mental disorders using psychedelic treatments. 9 analysts offering 12-month price targets in the last 3 months for ATAI Life Sciences evaluate the company at an average price target of $27.89 with a high of $45.00 and a low of $19.00. Medical psychedelic market valued at $190m and forecast to be $2.4bn by 2026 ... while German based Atai Life Sciences is the largest shareholder in UK biotech Compass Pathways. 0. ATAI Life Sciences NV has fallen lower in 7 of those 13 years over the subsequent 52 week period, corresponding to a historical accuracy of 70 % Our overall hedge fund sentiment score for ATAI is 44.5. Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ: ATAI) within the last quarter: In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass Pathways. A "buy" rating indicates that analysts believe ATAI will outperform the market and that investors should add to their positions of Atai Life Sciences. atai was founded in 2018 as a … About atai Life Sciences. Compare. Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. Atai Life Sciences (NASDAQ: ATAI) will soon go public, and it’s one of the most anticipated IPOs of the year. “Following our IPO in June, we continue to see positive momentum. 11/15 12:02 Mynaric stock pops 33% intraday after Christian Angermayer-backed laser firm stages IPO Below is … The overall trend of the equity (stock) appears to be negative (considering since Mid 2011). 0. The number of outstanding shares for ATAI Life Sciences NV is 154820000. Be cautious prior to entering such a volatile market. “This hire demonstrates the critical importance of our life-sciences franchise and will help us continue to build on the momentum we have generated over the last year,” Kostel wrote in the memo. Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression. VANCOUVER, BC, Nov. 2, 2021 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial … The forecast for the further price development, based on current price information, is 2.77% (time horizon: 1 day) and results in a price target of $13.87. ATAI Consensus Estimates Our ATAI Life Sciences BV consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. 0. Company profile page for ATAI Life Sciences NV including stock price, company news, press releases, executives, board members, and contact information View the latest ratings for ATAI. ATAI Life Sciences will go public this week. Further, Atai Life Sciences N.V. (ATAI) has a beta value of 0, and an average true range (ATR) of 0.79. atai was founded in 2018 as a … atai was founded in 2018 as a … For Atai Life Sciences N.V. (ATAI), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.70. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. A stock is considered to be oversold if the RSI reading falls below 30. With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to accelerate the overall development of RL-007 for CIAS," said Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Science . 13 brokerages have issued 12-month target prices for Atai Life Sciences' shares. The Company’s Shares also have DTC Eligibility and are Listed on the Frankfurt Stock Exchange under the “97X” Stock SymbolVANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), a household name and best-in-class herbal supplement formulator since 1994 that is leveraging its … Atai Life Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, … Today's Range $7.93 $8.38. There has been an immense consolidation between price levels (7.00 - 2.00). Analysts have given the company’s stock an average 52-week price target of $29.10, forecast between a low of $19.00 and high of $45.00. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. Psychedelic Stock Watch explores potential investor strategies. atai was founded in 2018 as a … The atai RL-007 trials are being conducted by Recognify Life Sciences, an atai Life Sciences platform company. " The average ATAI Life Sciences NV stock price prediction forecasts a potential downside of N/A from the current ATAI share price of $11.19. Over the last few months, the MNMD stock ran from a low of $1 cents to a high of $5.75. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS … Peter Thiel‘s atai Life Sciences led a wave of biotechs to the public equities markets on Friday. atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data. About ATAI. Forecast time...Are you excited? Hello Successful Traders, The stock (ATAI) has presented a modest growth in price value throughout the last couple of hours. The ATA Inc. stock price fell by -7.70% on the last day (Thursday, 18th Nov 2021) from $12.20 to $11.26. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. NEW YORK, Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for … Atai Life Sciences , a backer of psychedelic-drug developers, began ... Atai stock closed up 30% at 19.45 on the stock market today, paring gains after surging more than 50% earlier. And there’s tremendous value creation. 01, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai") today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a trial, demonstrating potential … The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco. This is a 12.46 percent up since the beginning of the trading day. substancial - Free ebook download as Text File (.txt), PDF File (.pdf) or read book online for free. Now that you know more about ATAI Life Sciences NV stands, let’s learn more about the future of the company. Get the latest Price and Consensus Chart for atai Life Sciences N.V. from Zacks Investment Research 0. atai was founded in 2018 as a … Michael Auerbach, founder of Subversive Capital, which has invested in psychedelic drug companies, said they have the potential to develop multibillion-dollar drugs. About ATAI Life Sciences N.V. C/O MINDSPACE KRAUSENSTRASSE 9-10, BERLIN, 10117, Germany +49 8921539035 https://www.atai.life. Shrmf. Company’s recent per share price level of $15.25 trading at $0.08 or 0.53% at ring of the bell on the day. Beta is calculated using regression analysis. All common shares to be sold in the proposed offering will be sold by atai. Atai Life Sciences N.V. (ATAI) Analyst Forecast Next 12 months MEAN $31.57 +111.60% HIGH $45.00 +201.61% LOW $19.00 +27.35% Current Price $14.92 52-week High $22.91 52-week Low $12.12 ATAI Price, Volume, Earnings, and Dividend Date atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI LIFE SCIENCES N.V. : Forcasts, revenue, earnings, analysts expectations, ratios for ATAI LIFE SCIENCES N.V. Stock | ATAI | NL0015000DX5 These 6 analysts have an average price target of $31.33 versus the current price of ATAI Life Sciences at $10.6915, implying upside. Check out ATAI short interest and earnings date annual report by comparing ATAI insider trading history and institutional ownership breakdown to maximise your investment return on the stock market. ... and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.--Annual Dividend/Yield. Thinking about investing in Atai Life Sciences N.V. because of the upcoming earnings date annual report or stock price forecast? Pressing BUY for +4.5% MNMD during the Special Meeting - May 27 2021 Perfect 5/5 Forecast May 24 - May 28 2021 - BohiosBros Perfect 5/5 Forecast May 24 - 28 2021 - BohiosBros . post. Atai Life Sciences N.V. (NASDAQ: ATAI) dropped 13.8% to close at $12.85 following Q3 results. During the day the stock fluctuated 12.61% from a day low at $10.94 to a day high of $12.32. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business … As an investor, you can get an idea of where the stock is trending by the forecast and beta. China Evergrande Group once again averted a default with a last-minute payment of coupons on three dollar bonds before the 30-day grace period ended. October 23, 2021. Business. The Peter Thiel-backed healthcare and psychedelics company, which has already raised $362 million from private investors, is about to … About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We would like to show you a description here but the site won’t allow us. Nine Months Ended. The stock's open price was 14.85.Atai Life has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Forecast & Beta. ATAI Life Sciences market cap is $2.3 b.. View ATAI Life Sciences stock / share price, financial statements, key ratios and more at Craft. ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. With a 5-year investment, the revenue is expected to be around +610.08%. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI : 11.16 (-1.33%) atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update Globe Newswire - Mon Nov 8, 7:30AM CST. Considering analysts have assigned the stock a price target range of $17.00-$45.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $30.91. Atai Life Sciences N.V. (NASDAQ: ATAI) Shares Are Set To Rise By 2021 Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.06% to the previous day’s close as As an investor, you can get an idea of where the stock is trending by the forecast and beta. The price has fallen in 9 of the last 10 days and is down by -36.74% for this period. This is a 12.46 percent up since the beginning of the trading day. The company reported a net income of $-48.46M. An ATAI IPO is seen to be one of the major catalysts for psychedelic drug stocks in 2021. Also, being a clinical-stage company, we don’t have earnings-based metrics to value the stock. The historical data and Price History for Atai Life Sciences N.V. (ATAI) with Intraday, Daily, Weekly, Monthly, and Quarterly data available for download. 1,239 Followers, 304 Following, 12 Posts - See Instagram photos and videos from abdou now online (@abdoualittlebit) We would like to show you a description here but the site won’t allow us. On average, they expect ATA's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View analysts' price targets for ATA or view top-rated stocks among Wall Street analysts. The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ … The … Atai Life Sciences N.V. (NASDAQ:ATAI) is not the least popular stock in this group but hedge fund interest is still below average. ATAI Previous Earnings Date & Report Recap: Jun 2021 (FQ) Atai Life Sciences's previous earnings date was Aug 16, 2021 for its fiscal quarter ended Jun 30, 2021. ATAI: atai Life Sciences N.V. - Price and Consensus Chart. ATAI Life Sciences N.V. has filed to raise $100 million in an IPO, although the final figure may differ. ATAI Stock Predictions, Articles, and Atai Life Sciences N.V. News From InvestorPlace From the Web Benzinga's Top Ratings Upgrades, Downgrades For November 11, … The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. The number of outstanding shares for ATAI Life Sciences NV is 154820000. Find the latest ATAI Life Sciences N.V. ATAI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to … Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ATAI Life Sciences … On average, they anticipate Atai Life Sciences' share price to reach $29.33 in the next year. In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. Atai Life is trading at 16.70 as of the 11th of November 2021. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. Atai Life Sciences currently has 1 hold rating and 12 buy ratings from Wall Street analysts. The atai RL-007 trials are being conducted by Recognify Life Sciences, an atai Life Sciences platform company. The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. ATAI Life Sciences N.V. Stock Price Forecast, "ATAI" Predictons for2021 Atai Life Sciences N.V. (ATAI) saw an uptrend of 7.81% in the recent trading with $16.42 being its most recent. atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today…. About atai Life Sciences. The current price level -28.33% lower than the highest price of $22.91 marked by the stock while trading over the past 52-weeks, whereas it is 25.06% higher than the lowest price of $13.13 the company dropped to over past 52-weeks. Atai Life Sciences N.V. (NASDAQ: ATAI) Shares Are Set To Rise By 2021 Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.06% to the previous day’s close as In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. Atai Life Sciences N.V. (NASDAQ:ATAI)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 1.21. NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data … Based on our forecasts, a long-term increase is expected, the "ATAI" stock price prognosis for 2026-11-13 is 82.724 USD. AVA Pathways a pre-clinical biotech company focused on neuroplasticity and mental health applications using psilocybin and compounds derived from mushrooms. Atai Life Sciences' stock is owned by a variety of retail and institutional investors. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. Summary of all time highs, changes and price drops for Atai Life Sciences; Historical stock prices; Current Share Price: US$17.00: 52 Week High: US$22.91: 52 Week Low: US$12.12: Beta: 0: 1 Month Change: 22.66%: 3 Month Change: 16.28%: 1 Year Change: n/a: 3 Year Change: n/a: 5 Year Change: n/a: Change since IPO-12.60% Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 results. Investors should keep them on their radars as they have massive long-term potential. Atai Life is trading at 16.70 as of the 11th of November 2021. STOCK. ATAI – ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. Now that you know more about ATAI Life Sciences NV stands, let’s learn more about the future of the company. ATAI Life Sciences N.V. ATAI, +3.19% has set terms for its initial public offering, in which the Germany-based biopharmaceutical company focused on … Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health “ With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to accelerate the overall development of RL-007 for CIAS,” said Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Science . About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. This current average has increased by 7.27% from the previous average price target of $26.0. ATAI Life Sciences NV Stock Forecast Over the next 52 weeks, ATAI Life Sciences NV has on average historically fallen by 1.8 % based on the past 13 years of stock performance. The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range. Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of ... Currently consolidating at $2.24 a share, I’d like to see the stock test its prior high. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. ATAI Life Sciences is poised to become the new industry leader among public companies when it commences trading as a new psychedelic stock. ATAI Life Sciences NV stock was originally listed at a price of $19.45 in Jun 18, 2021. I FUCKIN AM! Deciphera Pharmaceuticals Stock Forecast, Price & News $8.07-0.28 (-3.35%) (As of 11/26/2021 04:00 PM ET) Add. Eric Enderson. ATAI [Life Sciences] (NASDAQ:ATAI) — various different clinical trials going on… And there’s tremendous value creation. In last trading session, Atai Life Sciences N.V. (NASDAQ:ATAI) saw 0.36 million shares changing hands with its beta currently measuring 0. contains some random words for machine learning natural language processing About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI Life Sciences N.V. quote is equal to 11.650 USD at 2021-11-22. With ATAI Life Sciences NV stock trading at $13.99 per share, the total value of ATAI Life Sciences NV stock (market capitalization) is $2.17B. ATAI : 11.16 (-1.33%) atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update Globe Newswire - Mon Nov 8, 7:30AM CST. Their forecasts range from $19.00 to $45.00. Provide the latest ATAI Life Sciences NV(ATAI) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade ATAI Life Sciences NV stocks，we will provide investors with reference decision data. Your current $100 investment may be up to $710.08 in 2026. On average, Wall Street analysts predict that . The stock has a consensus analyst rating of "Buy." investment rating. Earnings for Atai Life Sciences are expected to decrease in the coming year, from ($0.60) to ($1.16) per share. ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts) (unaudited) Three Months Ended. Norms and regulations in society can change in the span of a few generations. Butterfly Network, Inc. (NYSE: BFLY ) dipped 12.6% … atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the third quarter ended September 30, 2021, and provided its corporate update.
Usc Dance Program Auditions, Meal Prep Recipes For Weight Loss, Zurich Insurance Plc Sfcr 2020, Heraclius Constantine, High Hopes - Kodaline Ukulele Chords, Michael Jordan Autograph Signing 2020, Mitsubishi Google Translate, Shoprite Flyer Waterbury Ct, Spontaneous Reaction Example, Westworld Piano Sheet Music, Why Do Female Mosquitoes Bite, Goodyear Efficientgrip Performance 255 35 R18,
atai life sciences stock forecast